Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Create a free account to read 3 full reports each month — plus a 14-day Pro trial. Get started →
AbbVie Inc.
ABBVHealthcareGenerated Jul 5, 2026, 08:09 PM UTC
ABBV (AbbVie Inc.) analytical snapshot. Revenue declined +6.4% YoY to $54.32B. Net margin at 8.95% (contracting ▼). Return on equity 146.26%, ROA 3.60%, ROIC 18.81%. Market cap $461.26B at $261.07 per share. Trailing P/E 95.98, P/S 8.49. EV/Operating income ≈ 40.48 (EV $516.37B). Risk: Moderate. Macro: Risk-on · Supportive. Composite analytical score -7 (data confidence 82%). Descriptive analytics from public filings — not investment advice.
Market cap
$461.26B
1.77B shares
Price
$261.07
NYQ
P/E (ttm)
95.98
Revenue (FY)
$54.32B
YoY -6.4%
Net margin
8.95%
▼ 1.12pp
Free cash flow
$22.06B
40.62% margin
Risk level
Moderate
Free SEC analysis
— computed from SEC filings, free to readFree previewFundamentals Analyst
Fundamentals
Fundamentals Analyst
score -25Deteriorating
80% conf
Revenue declined +6.4% YoY to $54.32B. Net margin at 8.95% (contracting ▼). Return on equity 146.26%, ROA 3.60%, ROIC 18.81%.
- Revenue declined +6.4% YoY to $54.32B.
- Net margin at 8.95% (contracting ▼).
- Return on equity 146.26%, ROA 3.60%, ROIC 18.81%.
- Gross margin 22.21%, operating margin 23.49%.
- Free cash flow margin 40.62% ($22.06B).
- Net income down ▼ +58.9% YoY.
- Debt/equity -9.69, current ratio 0.80, net debt $55.11B.
- Asset turnover 0.40 — capital efficiency.
Revenue (FY)
$54.32B
YoY -6.4%
Net margin
8.95%
▼ 1.12pp
ROE
146.26%
ROA 3.60%
ROIC
18.81%
EPS (diluted)
$2.72
FY2025
Free cash flow
$22.06B
40.62% margin
Debt / equity
-9.69
Cash $9.39B
Current ratio
0.80
Equity -$6.66B
Annual fundamentals — up to 10 years (SEC 10-K, US-GAAP)
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2016 | — | — | — | — | — | — | 39.49 |
| 2017 | — | — | — | — | — | — | 295.29 |
| 2018 | $25.64B | — | 19.20 | 36.43 | 23.22 | — | 150.90 |
| 2019 | $28.22B | +10.1% | 21.29 | 33.83 | 18.82 | $9.43B | 114.52 |
| 2020 | $32.75B | +16.1% | 28.01 | 19.49 | 17.36 | $12.79B | -69.59 |
| 2021 | $33.27B | +1.6% | 31.76 | 39.03 | 23.69 | $12.77B | 60.28 |
| 2022 | $45.80B | +37.7% | 23.91 | 24.81 | 10.08 | $16.79B | 29.96 |
| 2023 | $56.20B | +22.7% | 15.30 | 31.89 | 20.54 | $21.99B | 66.89 |
| 2024 | $58.05B | +3.3% | 18.44 | 31.21 | 20.39 | $24.25B | 114.25 |
| 2025 | $54.32B | -6.4% | 22.21 | 23.49 | 8.95 | $22.06B | 146.26 |
Quarterly revenue trend (last 6 quarters, SEC 10-Q)
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| Mar 31, 2025 | $13.34B | +8.4% | — | 9.64% |
| Jun 30, 2025 | $28.77B | +7.4% | +115.6% | 7.73% |
| Jun 30, 2025 | $15.42B | -42.4% | -46.4% | 14.42% |
| Sep 30, 2025 | $44.54B | +8.0% | +188.8% | 5.41% |
| Sep 30, 2025 | $15.78B | -61.7% | -64.6% | 15.28% |
| Mar 31, 2026 | $15.00B | +12.4% | -4.9% | 4.63% |
Revenue (annual, SEC 10-K)
2016: 0
2017: 0
2018: 25,638
2019: 28,216
2020: 32,753
2021: 33,266
2022: 45,804
2023: 56,197
2024: 58,054
2025: 54,318
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Profitability trends (%)
GrossOperatingNet
Free cash flow (annual)
2016: 0
2017: 0
2018: 0
2019: 9,431
2020: 12,789
2021: 12,772
2022: 16,790
2023: 21,990
2024: 24,248
2025: 22,062
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sources:SEC EDGAR — Company Facts (XBRL)
Free previewRegulatory Analyst
Filings & Ownership
Regulatory Analyst
score 30Improving
80% conf
Latest annual report (10-K) filed Feb 20, 2026. Latest quarterly report (10-Q) filed May 8, 2026. 16 recent 8-K material-event filings in the index.
- Latest annual report (10-K) filed Feb 20, 2026.
- Latest quarterly report (10-Q) filed May 8, 2026.
- 16 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
- ~10,000+ recent 13F-HR filings reference AbbVie Inc.; broad institutional reporting.
- Recent filers include THURSTON, SPRINGER, MILLER, HERD & TITAK, INC., K2 PRINCIPAL FUND, L.P., Saranac Partners Ltd.
- 1 recent 13D activist/beneficial-ownership filings — potential catalyst.
- 19 recent 13G passive institutional ownership notices.
Latest 10-K
Feb 20, 2026
Annual report
Latest 10-Q
May 8, 2026
8-K (recent)
16
Insider net
—
0B/0S
13F filers
10k+
Activist 13D
1
Recent 13F institutional filers (SEC EDGAR full-text)
| Filer | Form | Filed |
|---|---|---|
| THURSTON, SPRINGER, MILLER, HERD & TITAK, INC. | 13F-HR | May 14, 2024 |
| K2 PRINCIPAL FUND, L.P. | 13F-HR | Apr 30, 2015 |
| Saranac Partners Ltd | 13F-HR | Dec 5, 2025 |
| Pathway Financial Advisers, LLC | 13F-HR | Jul 19, 2024 |
| Pathway Financial Advisers, LLC | 13F-HR | Jul 19, 2024 |
Recent 8-K material events
| Date | Form | Description |
|---|---|---|
| Jun 22, 2026 | 8-K | FORM 8-K |
| May 12, 2026 | 8-K | FORM 8-K |
| Apr 29, 2026 | 8-K | 8-K |
| Apr 3, 2026 | 8-K | 8-K |
| Mar 4, 2026 | 8-K | FORM 8-K |
| Feb 26, 2026 | 8-K | FORM 8-K |
| Feb 4, 2026 | 8-K | 8-K |
| Jan 7, 2026 | 8-K | 8-K |
Free previewSEC Filing Analyst
SEC Filing Deep-Analysis
SEC Filing Analyst
score -24Deteriorating
68% conf
2 risk signal(s), 2 positive signal(s) detected from XBRL filing diff analysis. 2 positive signal(s) versus 2 risk signal(s). The filing exhibits more constructive indicators than concerns, though individual risk factors should still be monitored.
- Material weakness in internal controls: The term "material weakness" appears in 13 recent filing(s) (vs 2 in the prior period). This risk language is ongoing.
- NEW: Restatement of financial statements in latest filing: The term "restate" "financial statements" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 2 filing(s).
- Operating cash flow exceeds net income: OCF is 4.70x net income, indicating high earnings quality — cash conversion is strong and accruals are not inflating reported profits.
- Gross margin expansion: Gross margin expanded +3.8%pp (from 18.4% to 22.2%), indicating improved pricing power, cost efficiency, or favorable product mix.
- Endogenous analysis: 2 positive signal(s) versus 2 risk signal(s). The filing exhibits more constructive indicators than concerns, though individual risk factors should still be monitored.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- 1 new risk-language term(s) detected in filing text: Restatement of financial statements.
- Ongoing high-severity risk language: Material weakness in internal controls.
Revenue
$54.32B
-6.4% YoY
Gross profit
$12.07B
+12.7% YoY
Operating income
$12.76B
-29.6% YoY
Net income
$4.86B
-58.9% YoY
Operating cash flow
$22.84B
-8.4% YoY
Capex
$777.0M
+11.8% YoY
Total assets
$135.16B
+0.3% YoY
Long-term debt
$64.50B
-3.5% YoY
Filing quality score
70/100
stable
SEC XBRL metric changes (latest annual vs prior)
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $58.05B | $54.32B | $-3.74B | -6.4% |
| Gross profit | $10.71B | $12.07B | $1.36B | +12.7% |
| Operating income | $18.12B | $12.76B | $-5.36B | -29.6% |
| Net income | $11.84B | $4.86B | $-6.97B | -58.9% |
| Operating cash flow | $24.94B | $22.84B | $-2.10B | -8.4% |
| Capex | $695.0M | $777.0M | $82.0M | +11.8% |
| Total assets | $134.71B | $135.16B | $450.0M | +0.3% |
| Long-term debt | $66.84B | $64.50B | $-2.34B | -3.5% |
| Cash & equivalents | $12.81B | $5.52B | $-7.29B | -56.9% |
| Stockholders equity | $10.36B | $3.33B | $-7.04B | -67.9% |
| Inventory | $4.10B | $4.18B | $82.0M | +2.0% |
| Accounts receivable | $11.15B | $10.92B | $-236.0M | -2.1% |
| SG&A expense | $15.26B | $12.87B | $-2.39B | -15.6% |
| Interest expense | $2.23B | $2.22B | $-6.0M | -0.3% |
XBRL disclosure changes (new vs dropped concepts)
| Type | Concepts |
|---|---|
| Removed | AccountsPayableCurrent, AccruedIncomeTaxesNoncurrent, AccruedRoyaltiesCurrent, AdvertisingExpense, BusinessAcquisitionsProFormaNetIncomeLoss, BusinessAcquisitionsProFormaRevenue, BusinessCombinationContingentConsiderationLiabilityCurrent, BusinessCombinationContingentConsiderationLiabilityNoncurrent, CurrentFederalTaxExpenseBenefit, CurrentForeignTaxExpenseBenefit |
Risk language in filing text (EDGAR full-text search)
| Term | Severity | Recent | Prior | Status |
|---|---|---|---|---|
| Material weakness in internal controls | high | 13 | 2 | Ongoing |
| Restatement of financial statements | high | 2 | 0 | NEW |
| Impairment charge | medium | 34 | 7 | Ongoing |
| Restructuring | medium | 57 | 8 | Ongoing |
| Off-balance sheet arrangements | medium | 15 | 2 | Ongoing |
| Related party transactions | low | 2 | 0 | NEW |
Filing signal breakdown
Red flags: 2
Positive: 2
Watch: 0
Red flags
Positive
Watch
Unlock the rest
- ProValuationMarket cap $461.26B at $261.07 per share.
- ProPrice & TechnicalsPrice $261.07 — uptrend (above 200-DMA); 1-month momentum positive.
- ProMacro & RatesMarket regime: Risk-on · Supportive.
- ProRisk ScorecardComposite risk: Moderate.
This content is for Pro subscribers
Unlock the full breakdown from all analysts — valuation (DCF & Graham), price & technicals, macro, risk scorecard, and 13F/13D ownership flow — plus your research workspace.
3 sections free · 4 Pro sections locked · composite -7
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. AbbVie Inc. is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Macro regime
Risk-on · Supportive
Yield curve
Normal
VIX
16.59
Fed funds
3.63%
CPI YoY
+4.2%
Analytical read
deterministic previewPrice $261.07 — uptrend (above 200-DMA); 1-month momentum positive..
Risk
Moderate
Macro regime
Risk-on · Supportive
Macro exposure
Neutral
Descriptive analytics from public filings and macro data — not investment advice.
Peer comparison
Defensive groupHow ABBV stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| Bristol-Myers Squibb BMY | 12 | Neutral |
| Cigna Group CI | 9 | Neutral |
| Procter & Gamble PG | 9 | Neutral |
| UnitedHealth Group UNH | 6 | Neutral |
| CVS Health Corp. CVS | 6 | Neutral |
| Zoetis Inc. ZTS | 3 | Neutral |
| Eli Lilly & Co. LLY | 3 | Neutral |
| Colgate-Palmolive CL | 1 | Neutral |
| Coca-Cola Co. KO | 1 | Neutral |
| Gilead Sciences GILD | 1 | Neutral |
| Intuitive Surgical Inc. ISRG | -1 | Neutral |
| Moderna Inc. MRNA | -4 | Neutral |
| Regeneron Pharmaceuticals REGN | -4 | Neutral |
| DexCom Inc. DXCM | -7 | Neutral |
| AbbVie Inc. ABBV● you | -7 | Neutral |
| Johnson & Johnson JNJ | -7 | Neutral |
| Vertex Pharmaceuticals VRTX | -8 | Neutral |
| Kimberly-Clark Corp. KMB | -10 | Neutral |
| Sysco Corp. SYY | -10 | Neutral |
| Danaher Corp. DHR | -11 | Neutral |
| Mondelez International MDLZ | -11 | Neutral |
| Merck & Co. MRK | -11 | Neutral |
| Biogen Inc. BIIB | -11 | Neutral |
| Amgen Inc. AMGN | -14 | Neutral |
| HCA Healthcare HCA | -14 | Neutral |
| Illumina Inc. ILMN | -16 | Neutral |
| Kroger Co. KR | -16 | Neutral |
| Thermo Fisher Scientific TMO | -18 | Neutral |
| Costco Wholesale COST | -18 | Neutral |
| PepsiCo Inc. PEP | -21 | Neutral |
| Walmart Inc. WMT | -25 | Neutral |
| Hershey Co. HSY | -26 | Neutral |
| Abbott Laboratories ABT | -30 | Neutral |
| Pfizer Inc. PFE | -49 | Neutral |